Prostate Cancer Reports


Volume 1 Supplement 5
 May 2013
Home > Prostate Cancer Reports > Volume 1 - Year 2013 > Supplement 5, May 2013

CONTENTS



Clinical & Lab investigations
Localized PCa
Locally advanced PCa
Advanced PCa
Intermediate-risk PCa
High-risk PCa



CLINICAL & LAB INVESTIGATIONS


Statins

Mass AY, Agalliu I, Laze J, Lepor H.
Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis.
J Urol. 2012 Sep;188(3):786-91. doi: 10.1016/j.juro.2012.05.011. Epub 2012 Jul 19.
Abstract | Related citations


Functional outcomes

Hyun JS.
Prostate cancer and sexual function.
World J Mens Health. 2012 Aug;30(2):99-107. doi: 10.5534/wjmh.2012.30.2.99. Epub 2012 Aug 31.
Abstract | Full text | Related citations


Lymphadenectomy

Yuh BE, Ruel NH, Mejia R, Novara G, Wilson TG.
Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer.
BJU Int. 2013 Jan 25. doi: 10.1111/j.1464-410X.2012.11788.x. [Epub ahead of print]
Abstract | Related citations


Prostate-specific antigen

Patel S, Issa MM, El-Galley R.
Evaluation of novel formula of PSA, age, prostate volume, and race in predicting positive prostate biopsy findings.
Urology. 2013 Mar;81(3):602-6. doi: 10.1016/j.urology.2012.10.047. Epub 2013 Jan 9.
Abstract | Related citations


Recurrence

Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G.
(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.
Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):269-76.
Abstract | Related citations

LOCALIZED PROSTATE CANCER


Recurrence

Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA.
No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Urology. 2004 Mar;63(3):528-31.
Abstract | Related citations


Borque Á, del Amo J, Esteban LM, Ars E, Hernández C, Planas J, Arruza A, Llarena R, Palou J, Herranz F, Raventós CX, Tejedor D, Artieda M, Simon L, Martínez A, Carceller E, Suárez M, Allué M, Sanz G, Morote J.
Genetic predisposition to early recurrence in clinically localized prostate cancer.
BJU Int. 2013 Apr;111(4):549-58. doi: 10.1111/j.1464-410X.2012.11333.x. Epub 2012 Jul 3.
Abstract | Related citations


Eastham JA.
Words of wisdom. Re: Prostate cancer-specific survival following salvage radiotherapy versus observation in men with biochemical recurrence after radical prostatectomy. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. JAMA 2008;299:2760-9.
Eur Urol. 2009 Jan;55(1):247.
Abstract | Full text | Related citations


Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA.
Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):723-9.
Abstract | Related citations


Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Cancer J Sci Am. 1997 Mar-Apr;3(2):78-87.
Abstract | Related citations


Kupelian PA, Katcher J, Levin HS, Klein EA.
Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.
Abstract | Related citations


Kupelian P, Katcher J, Levin H, Zippe C, Klein E.
Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Urology. 1996 Aug;48(2):249-60.
Abstract | Related citations


Vicini FA, Ziaja EL, Kestin LL, Brabbins DS, Stromberg JS, Gonzalez JA, Martinez AA.
Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.
Urology. 1999 Jul;54(1):111-7.
Abstract | Related citations


Treatment

Oliai C, Lanciano R, Sprandio B, Yang J, Lamond J, Arrigo S, Good M, Mooreville M, Garber B, Brady LW.
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer.
J Radiat Oncol. 2013 Mar;2(1):63-70. Epub 2012 Sep 12.
Abstract | Full text | Related citations

LOCALLY ADVANCED PROSTATE CANCER


Recurrence

Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C, Morton G, Klotz L, Bhak E, Flavin A.
Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):674-80.
Abstract | Related citations

ADVANCED PROSTATE CANCER


Recurrence

Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED.
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
JAMA. 2006 Nov 15;296(19):2329-35.
Abstract | Full text | Related citations

INTERMEDIATE-RISK PROSTATE CANCER


Posttreatment surveillance

Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC.
The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort.
Mayo Clin Proc. 2012 Jun;87(6):540-7. doi: 10.1016/j.mayocp.2012.01.017.
Abstract | Full text | Related citations


Treatment

Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M; European Organization for Research and Treatment of Cancer.
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).
Lancet. 2005 Aug 13-19;366(9485):572-8.
Abstract | Full text | Related citations

HIGH-RISK PROSTATE CANCER


Recurrence

Ward JF, Blute ML.
Use and timing of radiotherapy in high-risk prostate cancer.
JAMA. 2004 Jun 16;291(23):2817; author reply 2817-8.
Abstract | Full text | Related citations


Treatment



Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups.
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).
Lancet. 2012 Dec 8;380(9858):2018-27. doi: 10.1016/S0140-6736(12)61253-7. Epub 2012 Oct 19.
Abstract | Related citations